Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Drug Evaluation Research ; (6): 1606-1609, 2017.
Artigo em Chinês | WPRIM | ID: wpr-664619

RESUMO

Objective To investigate the effects of atorvastatin and clopidogrel on coronary artery disease.Methods From August 2013 to January 2017,122 patients of acute coronary syndrome in our hospital for diagnosis and treatment were selected as the research object,all the patients were divided into observation group and control group of 61 case accorded to the random lottery envelopes randomly,two groups were treated with percutaneous coronary artery interventional therapy,the control group was given clopidogrel bisulfate adjuvant therapy,the observation group was given atorvastatin atorvastatin calcium and clopidogrel adjuvant therapy,all patients were observed for 4 weeks.Results The total effective rate of the observation group was significantly higher than that of the control group (P < 0.05).The LVEDD and LVESD values of the observation group and the control group after treatment were significantly lower than those before treatment (P < 0.05),while the LVEDD and LVESD values in the observation group were significantly lower than those in the control group (P < 0.05).The platelet membrane glycoprotein GP Ⅱb/Ⅲa values in the observation group and the control group atter treatment were (10.22 ± 3.12)% and (14.32 ± 2.98)% that were significantly lower than those before treatment of (20.98 ± 3.30)% and (21.22 ± 2.98)%,the observation group was significantly lower than the control group (P < 0.05).All patients were followed up for 6 months,the incidence of arrhythmia,bleeding and death in the observation group was 3.3%,so that was 19.7% in the control group,and the observation group was less than that of the control group (P < 0.05).Conclusion Atorvastatin atorvastatin calcium and clopidogrel adjuvant in patients with acute coronary syndrome therapy can improve heart function,reduce the expression ofplatelet membrane glycoprotein GP Ⅱb/Ⅲa,so as to improve the short-term and long-term efficacy.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA